Psychiatry drugs

Your source for up-to-date research on psychiatry drugs

For the latest information on advances in psychiatry drugs, turn to the deep collection of articles, studies, and research available on

As a leading resource for clinical psychiatry information and psychopharmacology research, offers access to evidence-based, peer-reviewed case reports, commentaries, Brief Reports, Academic Highlights, meta-analyses, and commentaries. On the pages of our website, you’ll find the latest research on psychiatry drugs as well as information in general psychiatry, child and adolescent psychiatry, functional psychiatry, integrated psychiatry, and other psychiatric disciplines.

Along with the most up-to-date research, offers the opportunity to earn CME credits on topics related to psychiatry drugs and other subjects. CME activities on are provided by the CME Institute ( of Physicians Postgraduate Press, Inc. The CME Institute is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Register on to access many of the resources the website has to offer. Or choose a subscription package for comprehensive access to all current and archived content on psychiatry drugs and other psychiatric subjects.

A leading resource for psychiatrists, mental health professionals, and PCPs offers a deep compendium of scientifically rigorous research into psychiatric diagnoses and treatment of many mental and neurologic illnesses. Through a wide range of peer-reviewed articles, you can easily stay on top of the latest developments in psychiatry drugs as well as other aspects of biological psychiatry, nutritional psychiatry, family psychiatry, geriatric psychiatry, and other subjects.

Articles published on include content drawn from two sources. The Journal of Clinical Psychiatry (JCP) is a leading psychiatric and psychopharmacology journal that has been a leading source of clinical information for more than 75 years. The Primary Care Companion for CNS Disorders (PCC) is dedicated to advancing the clinical expertise of primary care physicians and other practitioners by providing information of direct clinical utility as they care for patients with behavioral health and neuropsychiatric disorders.

Content on related to psychiatry drugs includes:


Explore Topic

Up-to-date CME activities on psychiatry drugs

When you become a registered user on, you will have access to 150+ CME activities along with new activities that are posted daily. Most activities are available at no charge and provide a convenient way to earn AMA PRA Category 1 Credits™.

As a registered user, you’ll also have access to MyCME, a free online tool from the CME Institute that keeps an online record of your activity and makes it easy to finish partially completed activities at a later time. Through your MyCME account, you can also print transcripts and certificates that document the credits you have earned.

CME activities related to psychiatry drugs include:

FAQs on research into psychiatry drugs

You may view a great deal of content concerning psychiatry drugs on by simply registering for free on the website. For complete access to all content, you’ll need a subscription to The Journal of Clinical Psychiatry.

JCP offers a combined print/online subscription as well as an online-only subscription. Visit the JCP subscription page for details and pricing.

Most CME activities on are free of charge. Occasionally, you may encounter a $10 processing fee on certain activities that lack commercial support.

A MyCME account is a free online tool provided by the CME Institute that keeps a record of your progress with CME activities on With a MyCME account, you can begin an activity at any time and return to finish it later. You may also print transcripts and certificates as soon as you have completed a CME activity.

Subscribe to gain complete access to information on psychiatry drugs

Subscribing to JCP is the best way to take advantage of all the research on psychiatry drugs available on As a subscriber, you can search the archives and view any article from any issue of the journal from 1997 to the present. You’ll also be able to view new issues of the journal online the moment they are published, and you’ll have access to new articles published online in JCP Weekly as well. Your subscription to JCP also includes access to many free benefits such as podcasts, email alerts, and CME activities.

Register for access to free articles, podcasts, and Elerts

If you’re not ready to subscribe to JCP, you can still take advantage of much that has to offer by simply registering for free as a user on the website. Your registration enables you to view the full text of supplements from JCP as well as the full text of all articles and supplements from PCC. You can participate in 150+ CME activities on the website and track your progress with a free MyCME account.

As a registered user, you can also sign up for Elerts – email alerts delivered daily to your inbox that notify you of new research on psychiatry drugs as well as new articles, reports, and CME activities on many other subjects. And you can subscribe to podcasts from to get an audio summary of the highlights of each issue of JCP and PCC.

About is published by Physicians Postgraduate Press, Inc., and is a leading source for the latest information, articles, research, and CME activities compiled from three sources: The Journal of Clinical Psychiatry (one of the 10 most-cited psychiatry research journals), The Primary Care Companion for CNS Disorders, and the CME Institute at

Material on offers lifelong learning opportunities for psychiatrists, mental health professionals, primary care physicians, and others who treat patients with mental and neurologic illnesses. Articles on touch on a wide variety of topics, including diagnosis of manic depression; treatment for frontotemporal dementiaADHD treatment for children and adults; diagnosing of disorganized schizophrenia; major depressive disorder symptoms; the latest psychotherapy techniques; and research into many other behavioral health and neuropsychiatric disorders.

Sign-up to stay
up-to-date today!


Already registered? Sign In

Original Research

Generalizability of the Results of Efficacy Trials in First-Episode Schizophrenia: Comparing Outcome and Study Discontinuation of Groups of Participants in the Optimization of Treatment and Management of Schizophrenia in Europe (OPTiMiSE) Trial

First-episode schizophrenia patients with suicidal ideation and substance use disorder are often excluded from clinical trials. Omitting...